Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The advent of checkpoint immunotherapy has dramatically changed the outcomes for patients with cancer. However, a considerable number of patients have little or no response to therapy. We review recent findings on the connection between the gut microbiota and the immune system, exploring whether this link could enhance the effectiveness of immunotherapy. RECENT FINDINGS: Clinical studies have reported specific types of bacteria in larger quantities at baseline in responders than in non-responders, especially Akkermansia mucinifila, Ruminococcaceae, Faecalibacterium, and Lachnospiraceae. Following the consumption of a high-fiber diet, bacteria in the gut ferment dietary fiber to short-chain fatty acids (SCFAs), like acetate, propionate, and butyrate. Some of the SCFAs nurture intestinal epithelial cells, and some enter the bloodstream. Here SCFAs can activate DC8 + cytotoxic T-cells to induce cancer cell death. High fiber intake in the diet was associated with a reduced risk of progression or death during checkpoint immunotherapy. Recent findings demonstrate that high-fiber plant-based diets such as the Mediterranean Diet positively influence the gut microbiota whereas antibiotics and proton pump inhibitors can negatively influence outcomes of cancer immunotherapy by changing the gut microbiota. This narrative review provides evidence of an association between types of bacteria and their metabolites and favorable responses to checkpoint immunotherapy. Prospective clinical trials are needed to determine if diet interventions can improve treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, α-diversity at baseline has been associated with favorable clinical outcomes in ICI therapies.5,147”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [147]
The cited source says what the claim attributes to it.
In the citing paper
“but this is two to three times the amount consumed today by an average Western person (Gamrath et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Gamrath et al., 2025
The cited source says what the claim attributes to it.
In the citing paper
“Patients can be motivated to change, and encouragement from family, friends, and healthcare providers can be significant motivating factors (Gamrath et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Gamrath et al., 2025
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, the American Gut Project—a large-scale, crowdfunded citizen science initiative focused on analyzing the human microbiome—collected samples from 10,000 individuals, which were then correlated with lifestyle, health, and disease questionnaires. Self-reported high-plant consumers exhibited a significantly more diverse gut microbiome (Gamrath et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Gamrath et al., 2025
In the citing paper
“Increasing the recommendation to 50 g daily should meet the requirements necessary to manipulate gut microbial composition, but this is two to three times the amount consumed today by an average Western person (Gamrath et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Gamrath et al., 2025
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 1×
“These cells contain genes that make up the human microbiome [4].”
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 2×
“Additionally, bacteria have been detected within solid tumors [8], but how they are associated with the gut micro-biome and their impact on human survival is still unclear [6].”
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“The bacterium, Prevotella, associated with a high-fiber diet [48], has been reported to correlate with treatment response in some studies [13, 29, 33, 38, 39].”
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 6×
“Akkermansia was also overrepresented in patients with progression-free survival (PFS) longer than 3 months compared to those with PFS shorter than 3 months [20].”
InfluentialRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“The human microbiota comprises 38 trillion (38 × 10 12 ) symbiotic microbial cells, primarily bacteria in the gut [3].”
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 5×
“However, several studies indicate that baseline bacterial diversity can predict treatment response [12–20]; specific bacteria, such as Akkermansia mucinifila, Ruminococcaceae, Fae-calibacterium, and Lachnospiraceae, are often found in greater quantities at baseline in responders compared to…”
InfluentialGut microbiota in human metabolic health and disease
Fan, Y., & Pedersen, O. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0433-9 · Cited by 4,724 · cited 1×
“Targeted therapies include bio-engineered commensals, targeted antibiotics, phage therapy, or Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) [11].”
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464 · cited 1×
“Additionally, bacteria have been detected within solid tumors [8], but how they are associated with the gut micro-biome and their impact on human survival is still unclear [6].”
The role of short chain fatty acids in health and disease
Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., & Macia, L. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800100-4.00003-9 · Cited by 2,425 · cited 1×
“They target G-protein-coupled receptors (GPCR) GPCR41, GPCR43, and GPCR109A [53] (Fig.”
Parker, B. J., Wearsch, P. A., Veloo, A. C. M., & Rodriguez-Palacios, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00906 · Cited by 1,701
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689 · cited 1×
“Instead of viewing bacteria and other microorganisms solely as infectious agents to be eradicated, the microbiota and the human host are now viewed as a super-organism or holobiont [1].”
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., Gurjao, C., Manders, F., Dalmasso, G., Stege, P. B., et al. (2020) · Nature · doi:10.1038/s41586-020-2080-8 · Cited by 1,208
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145 · cited 1×
“Or perhaps the specific type of bacteria is not as important as the metabolites [50] and/or the interactions between different bacteria strains [52].”
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966 · cited 8×
“Two trials in melanoma patients by Spencer et al. [28] and Pietrzak et al. [39]. indicated that a high intake of plant foods and dietary fiber was positively correlated with a better response to immunotherapy.”
InfluentialValid publication of the names of forty-two phyla of prokaryotes
Oren, A., & Garrity, G. M. (2021) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijsem.0.005056 · Cited by 921 · cited 1×
“The bacteria phylum formerly known as Firmicutes was renamed Bacillota in 2021 [46].”
American Gut: an Open Platform for Citizen-Science Microbiome Research
McDonalda, D., Hyde, E., Debelius, J. W., Morton, J. T., Gonzalez, A., Ackermann, G., Aksenov, A. A., Behsaz, B., Brennan, C., Chen, Y., et al. (2018) · doi:10.1101/277970 · Cited by 878 · cited 1×
“This finding aligns with current knowledge that different strains of bacteria metabolize different types of plant materials, so a more varied plant diet supports a wider variety of bacteria [56].”
Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics
Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J., & Martinez-Medina, M. (2017) · The ISME Journal · doi:10.1038/ismej.2016.176 · Cited by 874 · cited 1×
“The commensal Faecalibacterium is a genus of the Rumi-nococcus family and plays a role in breaking down dietary fiber, producing SCFAs [44].”
Impact of Omega-3 Fatty Acids on the Gut Microbiota
Costantini, L., Molinari, R., Farinon, B., & Merendino, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122645 · Cited by 741 · cited 1×
“Lachnospiraceae are bacteria that ferment resistant starch and dietary fiber to produce SFCAs [43–45].”
Microbes inside—from diversity to function: the case of Akkermansia
Belzer, C., & de Vos, W. M. (2012) · The ISME Journal · doi:10.1038/ismej.2012.6 · Cited by 715 · cited 4×
“This unique ligand specificity suggests that GPCR41 and GPCR43 may mediate the interaction between the gut microbiome and the human host correlation between serum butyrate levels and response to anti-PD-1 immunotherapy in patients with NSCLC [50].”
InfluentialFrankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
Jin, Y., Dong, H., Xia, L., Yang, Y., Zhu, Y., Shen, Y., Zheng, H., Yao, C., Wang, Y., & Lu, S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.007 · Cited by 573 · cited 3×
“During treatment, Prevotella copri remained enriched among responders [13].”
InfluentialZheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526 · cited 1×
“Some studies explore fecal microbiome transplantation (FMT) [10].”
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472
Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.044 · Cited by 398
Peng, Z., Cheng, S., Kou, Y., Wang, Z., Jin, R., Hu, H., Zhang, X., Gong, J.-F., Li, J., Lu, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1014 · Cited by 361 · cited 3×
“Within the sub-groups, there were differences in the microbiomes, but different Operational Taxonomic Units (OTUs) of Ruminococcus were consistently overrepresented in responders across all sub-groups [29].”
Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316 · cited 2×
“Among these, those with OS greater than 12 months had a more diverse microbiome than those with OS less than 12 months (p 0.05) [14].”
InfluentialMao, J., Wang, D., Long, J., Yang, X., Lin, J., Song, Y., Xie, F., Xun, Z., Wang, Y., Wang, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003334 · Cited by 275
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246 · cited 1×
“Antibiotic treatments reduce the effectiveness of immunotherapy in cancer patients [9], indicating the importance of the microbiome for response to immunotherapy.”
Abell, G. C. J., Cooke, C. M., Bennett, C. N., Conlon, M. A., & McOrist, A. L. (2008) · FEMS Microbiology Ecology · doi:10.1111/j.1574-6941.2008.00527.x · Cited by 230
Zhu, X., Li, K., Liu, G., Wu, R., Zhang, Y., Wang, S., Xu, M., Lu, L., & Li, P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2249143 · Cited by 220 · cited 2×
“Or perhaps the specific type of bacteria is not as important as the metabolites [50] and/or the interactions between different bacteria strains [52].”
Salgia, N. J., Bergerot, P. G., Maia, M. C., Dizman, N., Hsu, J., Gillece, J. D., Folkerts, M., Reining, L., Trent, J., Highlander, S. K., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.011 · Cited by 194 · cited 2×
“Several studies found Akkermansia significantly increased in responders to immunotherapy (Table 1) [15, 18, 20–26].”
InfluentialO'Keefe, S. J. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30257-2 · Cited by 186 · cited 1×
“Achieving this will require extensive education of healthcare professionals and the public [54, 55].”
The holobiont concept before Margulis
Baedke, J., Fábregas‐Tejeda, A., & Delgado, A. N. (2020) · Journal of Experimental Zoology Part B Molecular and Developmental Evolution · doi:10.1002/jez.b.22931 · Cited by 184
McKeown, N. M., Fahey, G. C., Jr., Slavin, J. L., & van der Kamp, J. W. (2022) · BMJ · doi:10.1136/bmj-2020-054370 · Cited by 175 · cited 2×
“Achieving this will require extensive education of healthcare professionals and the public [54, 55].”
Vitamin D regulates microbiome-dependent cancer immunity
Giampazolias, E., Pereira da Costa, M., Lam, K. C., Lim, K. H. J., Cardoso, A., Piot, C., Chakravarty, P., Blasche, S., Patel, S., Biram, A., et al. (2024) · Science · doi:10.1126/science.adh7954 · Cited by 151 · cited 2×
“This part of the study did unfortunately not correlate outcomes to the microbiome [58].”
Skin Exposure to Narrow Band Ultraviolet (UVB) Light Modulates the Human Intestinal Microbiome
Bosman, E. S., Albert, A. Y., Lui, H., Dutz, J. P., & Vallance, B. A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02410 · Cited by 143 · cited 2×
“Additionally, both alpha and beta diversity of the microbiome increased after UVB exposure [60].”
Modern vision of the Mediterranean diet
Kiani, A. K., Medori, M. C., Bonetti, G., Aquilanti, B., Velluti, V., Matera, G., Iaconelli, A., Stuppia, L., Connelly, S., Herbst, K. L., et al. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2745 · Cited by 105 · cited 1×
“This traditional diet also incorporates ancient grains, honey, and wine [57].”
Newsome, R. C., Gharaibeh, R. Z., Pierce, C. M., da Silva, W. V., Paul, S., Hogue, S. R., Yu, Q., Antonia, S., Conejo-Garcia, J. R., Robinson, L. A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01037-7 · Cited by 104 · cited 2×
“Several studies found Akkermansia significantly increased in responders to immunotherapy (Table 1) [15, 18, 20–26].”
Kostine, M., Mauric, E., Tison, A., Barnetche, T., Barre, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.036 · Cited by 101 · cited 1×
“The data were not correlated with microbiome measurements, so it is unclear whether these effects are due to changes in the microbiome or other mechanisms [61].”
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100 · cited 1×
“However, adding Clostridium butyricum to the treatment regimen reversed the negative effect of PPI usage [64].”
Pomegranate ellagitannins stimulate the growth of Akkermansia muciniphila in vivo
Henning, S. M., Summanen, P. H., Lee, R., Yang, J., Finegold, S. M., Heber, D., & Li, Z. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.12.003 · Cited by 94
Song, P., Yang, D., Wang, H., Cui, X., Si, X., Zhang, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13442 · Cited by 83 · cited 1×
“Recent studies have found that certain species of archaea are more abundant in patients who respond well to immunotherapy or chemo-immunotherapy (Table 1) [17, 30, 40].”
The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
Han, Z., Cheng, S., Dai, D., Kou, Y., Zhang, X., Li, F., Yin, X., Ji, J., Zhang, Z., Wang, X., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1312 · Cited by 82 · cited 3×
“In a study by Han et al. involving patients with HER2-negative gastric cancer, significant enrichment of Lactobacillus and two species, L. mucosae, and L. salivarius, was found in responders to immunotherapy or chemo-immu-notherapy, not only at baseline but also during treatment [30].”
Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
Ren, S., Feng, L., Liu, H., Mao, Y., & Yu, Z. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15303 · Cited by 77 · cited 2×
“SCFAs were elevated in responders compared to non-responders ( p = 0.0095) [16].”
InfluentialLopes, S., Pabst, L., Dory, A., Klotz, M., Gourieux, B., Michel, B., & Mascaux, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070076 · Cited by 75 · cited 1×
“They concluded that PPI use negatively affects both OS and PFS in patients receiving immunotherapy [66].”
Wind, T. T., Gacesa, R., Vich Vila, A., de Haan, J. J., Jalving, M., Weersma, R. K., & Hospers, G. A. P. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000656 · Cited by 73
Grenda, A., Iwan, E., Chmielewska, I., Krawczyk, P. A., Giza, A., Bomba, A., Frąk, M., Rolska-Kopińska, A., Szczyrek, M., Kieszko, R., et al. (2022) · AMB Express · doi:10.1186/s13568-022-01428-4 · Cited by 71 · cited 2×
“Age was also a significant factor; patients younger than 66 had significantly lower levels of Akkermansia compared to older patients [25].”
Peiffer, L. B., White, J. R., Jones, C. B., Slottke, R., Ernst, S. E., Moran, A. E., Graff, J. N., & Sfanos, K. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100822 · Cited by 63 · cited 1×
“Conversely, in a study of patients with prostate cancer treated with pembrolizumab, higher levels of Akkermansia were correlated with worse outcomes, however these were not statistically significant ( p = 0.201) [37].”
InfluentialA Humble Bacterium Sweeps This Year's Nobel Prize
Mégraud, F. (2005) · Cell · doi:10.1016/j.cell.2005.11.032 · Cited by 59 · cited 1×
“Helicobacter pylori, identified in 1982, was the only bacterial species linked to cancer until recently [5].”
Galus, Ł., Michalak, M., Lorenz, M., Stoińska‐Swiniarek, R., Tusień-Małecka, D., Galus, A., Kolenda, T., Leporowska, E., & Mackiewicz, J. (2023) · Cancer · doi:10.1002/cncr.34718 · Cited by 58 · cited 1×
“Unfortunately, this trial did not investigate the effect on the microbiome [59].”
Hoedjes, M., Nijman, I., & Hinnen, C. (2022) · Cancers · doi:10.3390/cancers14082026 · Cited by 55 · cited 1×
“Patients saw lifestyle changes as a positive way to gain control [67].”
Zhu, C., Wang, Y., Zhu, R., Wang, S., Xue, J., Zhang, D., Lan, Z., Zhang, C., Liang, Y., Zhang, N., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00607-8 · Cited by 49 · cited 3×
“Zhu et al. found that in patients with biliary cancer on treatment with anti-PD-1/anti-PD-L1, beta-diversity differed between those who derived durable benefits from the treatment and those who did not [19].”
InfluentialZhao, H., Li, D., Liu, J., Zhou, X., Han, J., Wang, L., Fan, Z., Feng, L., Zuo, J., & Wang, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.5312 · Cited by 49
Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota
He, D., Li, X., An, R., Wang, L., Wang, Y., Zheng, S., Chen, X., & Wang, X. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00171-3 · Cited by 46
HAMADA, K., YOSHIMURA, K., HIRASAWA, Y., HOSONUMA, M., MURAYAMA, M., NARIKAWA, Y., ARIIZUMI, H., OHKUMA, R., SHIDA, M., KUBOTA, Y., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15312 · Cited by 43 · cited 3×
“For instance, a study by Peng et al. on 233 cancer patients found no difference between PPI users and non-PPI users [65], and the same was true for Hamada´s study on 69 patients with NSCLC [62].”
InfluentialYin, H., Yang, L., Peng, G., Yang, K., Mi, Y., Hu, X., Hao, X., Jiao, Y., Wang, X., & Wang, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0450 · Cited by 40
Peng, K., Chen, K., Teply, B. A., Yee, G. C., Farazi, P. A., & Lyden, E. R. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211033938 · Cited by 40 · cited 1×
“For instance, a study by Peng et al. on 233 cancer patients found no difference between PPI users and non-PPI users [65], and the same was true for Hamada´s study on 69 patients with NSCLC [62].”
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Zhang, M., Bzura, A., Baitei, E. Y., Zhou, Z., Spicer, J., Poile, C., Rogel, J., Branson, A., King, A., Barber, S. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49842-5 · Cited by 38 · cited 1×
“The bacterium, Prevotella, associated with a high-fiber diet [48], has been reported to correlate with treatment response in some studies [13, 29, 33, 38, 39].”
Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Galus, Ł., Mackiewicz, J., Kaczmarek, M., Mackiewicz, A., & Schmidt, M. (2022) · Cancers · doi:10.3390/cancers14215369 · Cited by 36
Fang, C., Fang, W., Xu, L., Gao, F., Hou, Y., Zou, H., Ma, Y., Moll, J. M., Yang, Y., Wang, D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837525 · Cited by 31 · cited 4×
“Several studies found Akkermansia significantly increased in responders to immunotherapy (Table 1) [15, 18, 20–26].”
InfluentialHarvey, B. I., Youngblood, S. M., & Kleckner, A. S. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2192891 · Cited by 30 · cited 2×
“Barriers included chemotherapy side effects and food preferences [69].”
Xu, L., Qi, Y., Jiang, Y., Ji, Y., Zhao, Q., Wu, J., Lu, W., Wang, Y., Chen, Q., & Wang, C. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1165 · Cited by 29 · cited 1×
“The bacterium, Prevotella, associated with a high-fiber diet [48], has been reported to correlate with treatment response in some studies [13, 29, 33, 38, 39].”
Zeng, Y., Shi, Q., Liu, X., Tang, H. T., Lu, B., Zhou, Q., Xu, Y., Chen, M., Zhao, J., Li, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144534 · Cited by 26
McHugh, A., O’Connell, E., Gurd, B., Rae, P., George, E. S., Kleckner, A. S., & Baguley, B. J. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01426-8 · Cited by 22 · cited 2×
“These results indicate that dietary interventions are feasible for patients undergoing cancer treatment [68].”
Gut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20 · cited 1×
“For patients undergoing chemo-immunotherapy for NSCLC, B. breve has been identified as an independent prognostic factor for PFS (p 0.05) and could potentially serve as a biomarker to predict the efficacy of immuno-chemotherapy in NSCLC patients [47].”
InfluentialCheng, X., Wang, J., Gong, L., Dong, Y., Shou, J., Pan, H., Yu, Z., & Fang, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185479 · Cited by 20 · cited 1×
“Recent studies have found that certain species of archaea are more abundant in patients who respond well to immunotherapy or chemo-immunotherapy (Table 1) [17, 30, 40].”
Cantarelli, L., Gutiérrez Nicolás, F., García Gil, S., Morales Barrios, J. A., Oramas Rodriguez, J., & Nazco Casariego, G. J. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000494 · Cited by 4 · cited 2×
“The study suggested a treatment window where starting PPIs four weeks after initiating immunotherapy might mitigate their negative effects [63].”
Cited by
Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy
Luo, W., Li, R., Pan, C., & Luo, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1710880 · Cited by 59
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications
Rezazadeh‐Gavgani, E., Majidazar, R., Lotfinejad, P., Kazemi, T., & Shamekh, A. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70196 · Cited by 56
Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
Huang, M., Zhang, Y., Chen, Z., Yu, X., Luo, S., Peng, X., & Li, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107726 · Cited by 34
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
“15,77,88,146,147 However, mouse models have highlighted inconsistencies in treatment outcomes following supplementation with SCFAs.”
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Metadata
- Authors
- Gamrath, L., Pedersen, T. B., Møller, M. V., Volmer, L. M., Holst-Christensen, L., Vestermark, L. W., & Donskov, F.
- Affiliations
- Hospital South West Jutland (DK)
- Vejle Sygehus (DK)
- University of Southern Denmark (DK)
- Corresponding author
- Donskov, Frede
- ORCID
- Donskov, Frede
- Venue
- Current Oncology Reports
- Published
- 2025-01
- Volume
- 27
- Issue
- 1
- Pages
- 45-58
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- PMC
- PMC11762419
- OpenAlex
- W4406026483
- Cited by
- 30
- References
- 69
- Citations by year
- 2026: 17 · 2025: 13
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 2 d)
- Locations
- Current Oncology Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
- Funders
- Southwest-Southern Denmark Cancer Fund
- Danish Cancer Society, Esbjerg
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, treatment response, Ruminococcaceae, Faecalibacterium, Lachnospiraceae, short-chain fatty acids, dietary fiber, high-fiber diet, plant-based diet, Mediterranean diet, antibiotics, proton pump inhibitors, dendritic cells, intestinal epithelium
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Bacteria, Clinical Trials as Topic, Diet, Dietary Fiber, Humans, Immunotherapy, Neoplasms, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.